Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 11/14/14 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
54 |
| 11/14/14 | 8-K | Current report filing |
|
13 | |
| 10/16/14 | UPLOAD | SEC-generated letter |
|
3 | |
| 10/02/14 | 8-K | Current report filing |
|
7 | |
| 09/24/14 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
12 | |
| 09/17/14 | 8-K/A | Current report filing |
|
27 | |
| 09/10/14 | 8-K | Current report filing |
|
27 | |
| 09/05/14 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 09/03/14 | DEF 14A | Definitive proxy statements |
|
38 | |
| 08/26/14 | UPLOAD | SEC-generated letter |
|
5 |
